TY - JOUR
T1 - TFAM is a novel mediator of immunogenic cancer cell death
AU - Yang, Minghua
AU - Li, Changfeng
AU - Zhu, Shan
AU - Cao, Lizhi
AU - Kroemer, Guido
AU - Zeh, Herbert
AU - Tang, Daolin
AU - Kang, Rui
N1 - Publisher Copyright:
© 2018 The Author(s). Published with license by Taylor & Francis Group, LLC © 2018, © Minghua Yang, Changfeng Li, Shan Zhu, Lizhi Cao, Guido Kroemer, Herbert Zeh, Daolin Tang and Rui Kang.
PY - 2018/6/3
Y1 - 2018/6/3
N2 - Immunogenic cell death (ICD) is a type of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs) and results in a dead-cell antigen-specific immune response. Here, we report that spautin-1, an inhibitor of ubiquitin-specific peptidases, triggers immunogenic cancer cell death in vitro and in vivo. The anticancer activity of spautin-1 occurs independent of autophagy inhibition, but depends on the intrinsic mitochondrial apoptosis pathway. Spautin-1 causes mitochondrial oxidative injury, which results in JUN transcription factor activation in a JNK-dependent manner. Mechanistically, activation of JUN by spautin-1 leads to apoptosis by upregulation of pro-apoptotic BAD expression. Importantly, the release of TFAM, a mitochondrial DAMP, by apoptotic cells may contribute to spautin-1-induced ICD via its action on the receptor AGER. Indeed, cancer cells treated with spautin-1 in vitro were able to elicit an anticancer immune response when inoculated in vivo, in the absence of any adjuvant. This immunogenic effect of spautin-1-treated cancer cells was lost when TFAM or AGER were neutralized by specific antibodies. Altogether, our results suggest that spautin-1 may stimulate an apoptotic pathway that results in ICD, in TFAM- and AGER-dependent fashion.
AB - Immunogenic cell death (ICD) is a type of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs) and results in a dead-cell antigen-specific immune response. Here, we report that spautin-1, an inhibitor of ubiquitin-specific peptidases, triggers immunogenic cancer cell death in vitro and in vivo. The anticancer activity of spautin-1 occurs independent of autophagy inhibition, but depends on the intrinsic mitochondrial apoptosis pathway. Spautin-1 causes mitochondrial oxidative injury, which results in JUN transcription factor activation in a JNK-dependent manner. Mechanistically, activation of JUN by spautin-1 leads to apoptosis by upregulation of pro-apoptotic BAD expression. Importantly, the release of TFAM, a mitochondrial DAMP, by apoptotic cells may contribute to spautin-1-induced ICD via its action on the receptor AGER. Indeed, cancer cells treated with spautin-1 in vitro were able to elicit an anticancer immune response when inoculated in vivo, in the absence of any adjuvant. This immunogenic effect of spautin-1-treated cancer cells was lost when TFAM or AGER were neutralized by specific antibodies. Altogether, our results suggest that spautin-1 may stimulate an apoptotic pathway that results in ICD, in TFAM- and AGER-dependent fashion.
UR - http://www.scopus.com/inward/record.url?scp=85042118545&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2018.1431086
DO - 10.1080/2162402X.2018.1431086
M3 - Article
C2 - 29872558
AN - SCOPUS:85042118545
SN - 2162-4011
VL - 7
JO - OncoImmunology
JF - OncoImmunology
IS - 6
M1 - e1431086
ER -